Unknown

Dataset Information

0

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.


ABSTRACT: Axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, will be used in combination first-line therapies against metastatic renal cell carcinoma (mRCC), but its effects as a first-line monotherapy are unclear. Thus, we aimed to elucidate pretreatment clinical factors that predict the prognosis of patients with mRCC receiving first-line axitinib therapy. We enrolled 63 patients with mRCC treated with axitinib as first-line therapy between Nov. 2003 and Jul. 2018. Progression-free survival (PFS) and overall survival (OS) were assessed using the Wald ?2 statistic in Cox proportional hazards regression. Median patient age was 67 (range: 25-85) years. Seven (11.1%) patients were classified as being at favorable risk, 33 (52.4%) at intermediate risk, and 23 (36.5%) at poor risk according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification system. Median follow-up duration after axitinib initiation was 14 (range: 1-72) months. Median PFS and OS were 18 months and 65 months, respectively. Cox regression analyses of clinical predictors revealed that high C-reactive protein (CRP) levels were significantly correlated with shorter PFS [hazard ratio (HR), 1.63; 95% confidence interval (CI) 1.7-4.0)], whereas spindle cells and poor IMDC risk scores were related to worse OS (HR, 2.87 and 2.88, respectively; 95% CI 1.4-11.0 and 1.1-8.5, respectively). Thus, patients with mRCC and spindle histology or poor IMDC risk scores had worse OS, and those with high CRP levels had shorter PFS in first-line axitinib treatment. Other therapies might be more suitable for initial management of such patients.

SUBMITTER: Numakura K 

PROVIDER: S-EPMC7675987 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.

Numakura Kazuyuki K   Kobayashi Mizuki M   Muto Yumina Y   Sekine Yuya Y   Takahashi Makoto M   Kashima Soki S   Yamamoto Ryohei R   Koizumi Atsushi A   Nara Taketoshi T   Saito Mitsuru M   Narita Shintaro S   Nanjyo Hiroshi H   Habuchi Tomonori T  

Scientific reports 20201118 1


Axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, will be used in combination first-line therapies against metastatic renal cell carcinoma (mRCC), but its effects as a first-line monotherapy are unclear. Thus, we aimed to elucidate pretreatment clinical factors that predict the prognosis of patients with mRCC receiving first-line axitinib therapy. We enrolled 63 patients with mRCC treated with axitinib as first-line therapy between Nov. 2003 and Jul. 2018. Progre  ...[more]

Similar Datasets

| S-EPMC7471136 | biostudies-literature
| S-EPMC5480076 | biostudies-literature
| S-EPMC3873008 | biostudies-other
| S-EPMC4120767 | biostudies-literature
| S-EPMC8419787 | biostudies-literature
| S-EPMC3585900 | biostudies-other
| S-EPMC5371698 | biostudies-other
| S-EPMC7225300 | biostudies-literature
| S-EPMC4219683 | biostudies-literature
| S-EPMC7443011 | biostudies-literature